iparomlimab + tuvonralimab (Qilu Pharmaceutical, 55d03a)

**Iparomlimab + tuvonralimab** is a fixed-ratio PD-1/CTLA-4 immune-checkpoint antibody combination developed by Qilu Pharmaceutical and marketed in China as **齐倍安**. It combines iparomlimab, an anti-PD-1 IgG4 monoclonal antibody, with tuvonralimab, an anti-CTLA-4 IgG1 monoclonal antibody engineered for a shorter elimination half-life. The product blocks PD-1- and CTLA-4-mediated inhibitory signaling to enhance antitumor T-cell activity; CTLA-4 targeting can also promote depletion of intratumoral regulatory T cells through antibody-dependent cellular cytotoxicity. It received conditional marketing approval in China for recurrent or refractory cervical cancer after progression on platinum-based chemotherapy and is being evaluated in several solid tumors, including locally advanced nasopharyngeal carcinoma. ([english.nmpa.gov.cn](https://english.nmpa.gov.cn/2025-02/19/c_1073649.htm))

Brand names

齐倍安

Other names

epalorlimo-verilimumabiparomlimab and tuvonralimabPD-1/CTLA-4 MabPair艾帕洛利托沃瑞利单抗